Gryphon Financial Partners’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,400
| Closed | -$178K | – | 242 |
|
|
2022
Q2 | $178K | Buy |
2,400
+65
| +3% | +$4.82K | 0.04% | 182 |
|
|
2022
Q1 | $210K | Buy |
2,335
+50
| +2% | +$4.5K | 0.04% | 185 |
|
|
2021
Q4 | $256K | Buy |
2,285
+15
| +0.7% | +$1.68K | 0.05% | 177 |
|
|
2021
Q3 | $285K | Sell |
2,270
-270
| -11% | -$33.9K | 0.06% | 157 |
|
|
2021
Q2 | $344K | Sell |
2,540
-100
| -4% | -$13.5K | 0.08% | 131 |
|
|
2021
Q1 | $358K | Buy |
2,640
+30
| +1% | +$4.07K | 0.08% | 123 |
|
|
2020
Q4 | $367K | Buy |
2,610
+20
| +0.8% | +$2.81K | 0.09% | 110 |
|
|
2020
Q3 | $289K | Buy |
2,590
+20
| +0.8% | +$2.23K | 0.09% | 120 |
|
|
2020
Q2 | $288K | Sell |
2,570
-20
| -0.8% | -$2.24K | 0.09% | 108 |
|
|
2020
Q1 | $201K | Buy |
+2,590
| New | +$201K | 0.07% | 134 |
|
|
2018
Q3 | – | Sell |
-170
| Closed | -$16K | – | 849 |
|
|
2018
Q2 | $16K | Hold |
170
| – | – | 0.01% | 419 |
|
|
2018
Q1 | $15K | Sell |
170
-86
| -34% | -$7.59K | 0.01% | 442 |
|
|
2017
Q4 | $22K | Buy |
+256
| New | +$22K | 0.01% | 385 |
|